15.3 Adverse Reactions, Patient Safety & Emergency Management

Adverse Reactions, Patient Safety & Emergency Management

Core Clinical Mandate: Intravenous sodium fluorescein is a diagnostic pharmacological agent with an established safety profile, but it is not benign. The overall incidence of adverse events ranges between 5% and 10%. Certified Ophthalmic Medical Technologists (COMTs) must maintain immediate readiness to distinguish benign, self-limiting side effects from acute, life-threatening anaphylactoid collapse, and must be proficient in emergency crash-cart mobilization and drug administration protocols.

---

Epidemiology and Classification of Adverse Fluorescein Reactions

Adverse events associated with sodium fluorescein administration are systematically classified into three clinical severity tiers based on symptomatology and required therapeutic intervention:

1. Mild Reactions (Incidence ~5% to 10%)

Mild reactions are transient, self-limiting, and resolve spontaneously within several minutes without specific medical intervention or pharmacotherapy:

• Nausea: The most frequent adverse reaction, occurring in approximately 3% to 10% of patients. It characteristically develops 30 to 60 seconds post-injection (corresponding to the arrival of the concentrated dye bolus at the brainstem area postrema / chemoreceptor trigger zone), lasts for 1 to 3 minutes, and subsides spontaneously.
• Vomiting / Emesis: Occurs in 1% to 2% of patients, usually immediately following the initial wave of nausea. Emesis basins must always be within arm's reach of the patient during angiography.
• Autonomic / Mild Allergic Manifestations: Lightheadedness, mild dizziness, flushing, feeling of warmth, metallic taste in the mouth, localized pruritus, and transient paroxysmal sneezing.
• Expected Physiological Side Effects: Yellow-orange chromaturia (lasting 24–36 hours) and cutaneous/scleral jaundice (lasting 6–12 hours) are universal physiological consequences of dye clearance and do not constitute adverse drug reactions.

2. Moderate Reactions (Incidence ~1%)

Moderate reactions are not immediately life-threatening but cause substantial patient distress and require prompt, targeted pharmacologic intervention:

• Urticaria (Hives): Widespread cutaneous wheals and erythema, often accompanied by intense pruritus.
• Angioedema: Soft-tissue swelling involving the periorbital area, lips, or extremities, without acute airway or laryngeal compromise.
• Bronchospasm / Wheezing: Mild-to-moderate reactive airway constriction with audible expiratory wheezes, but maintaining oxygen saturation >92%.
• Vasovagal Syncope: Sudden parasympathetic outflow resulting in bradycardia and systemic hypotension, causing transient loss of consciousness.
• Local Thrombophlebitis: Chemical vein irritation or superficial phlebitis at the venipuncture site.

3. Severe / Life-Threatening Reactions (Incidence ~1 in 1,900 to 1 in 2,000)

Severe reactions represent acute medical emergencies requiring immediate cardiopulmonary resuscitation, emergency team activation (Code Blue / 911), and aggressive intensive care management:

• Anaphylactic Shock: Acute cardiovascular collapse characterized by profound distributive hypotension (systolic blood pressure <90 mmHg), marked tachycardia, and peripheral hypoperfusion.
• Laryngeal Edema: Massive supraglottic swelling leading to acute upper airway obstruction, inspiratory stridor, and asphyxia.
• Severe Bronchospasm: Critical lower airway obstruction, severe dyspnea, cyanosis, and arterial hypoxemia.
• Cardiovascular Events: Acute myocardial infarction, severe ventricular arrhythmias, or circulatory arrest.
• Neurological Manifestations: Generalized tonic-clonic seizures.
• Mortality Rate: Estimated at approximately 1 in 220,000 angiographic procedures.

---

Pathophysiological Mechanisms: Pseudoallergy vs. Type I Hypersensitivity

Historically, fluorescein reactions were presumed to be classical IgE-mediated (Type I) allergic hypersensitivity events. Extensive immunological research has fundamentally refuted this concept:

Pathophysiology of Fluorescein Reactions:
Predominantly NON-IgE ANAPHYLACTOID (Pseudoallergic) Reaction:
Direct Complement Activation (C3a, C5a) + Direct Mast Cell Histamine De-granulation
(Does NOT require prior sensitizing exposure; skin testing has ZERO predictive validity)

1. Non-IgE-Mediated (Anaphylactoid / Pseudoallergic) Activation: The vast majority of severe reactions result from direct complement activation (generating anaphylatoxins C3a and C5a) and direct, non-immunological degranulation of basophils and mast cells, causing massive systemic release of histamine, tryptase, leukotrienes, and prostaglandins without preformed IgE antibodies.
2. No Prior Exposure Required: Because the mechanism is non-IgE-mediated, patients can develop severe, life-threatening anaphylactoid reactions upon their first lifetime exposure to sodium fluorescein.
3. Inefficacy of Skin Prick / Intradermal Testing: Intradermal or skin prick testing has a near-zero positive predictive value for forecasting anaphylactoid reactions and is clinically contraindicated as a predictive screening tool. Furthermore, the intradermal test dose itself can trigger severe systemic reactions.

Dispelling the Iodine and Shellfish Cross-Reactivity Myth

A pervasive and hazardous clinical misconception in ophthalmology is that patients with known allergies to shellfish or radiopaque iodinated CT contrast media cannot receive sodium fluorescein:

• Molecular Reality: Sodium fluorescein (C₂₀H₁₀Na₂O₅) is a synthetic hydrocarbon resorcinolphthalein dye. It contains zero iodine molecules.
• No Cross-Reactivity: Shellfish allergy is mediated by IgE antibodies directed against muscle tropomyosin, a muscle protein found in crustaceans and mollusks. It has absolutely no relationship to iodine or fluorescein.
• Clinical Ruling: A documented history of seafood or radiocontrast dye allergy is NOT a contraindication to sodium fluorescein angiography.
• Critical Distinction: In contrast to sodium fluorescein, Indocyanine Green (ICG) contains approximately 5% sodium iodide by weight; therefore, ICG is strictly contraindicated in patients with true iodine hypersensitivity.

Emergency Preparedness and Rapid Clinical Response Protocols

Every ophthalmic imaging facility performing fluorescein angiography must maintain a fully stocked, routinely inspected Emergency Crash Cart, portable suction, oxygen delivery systems, and an automated external defibrillator (AED) in the immediate imaging suite.

Step-by-Step Acute Emergency Management Algorithm

1. Halt the Injection Immediately: At the earliest sign of severe respiratory distress, stridor, hypotension, or angioedema, stop injecting fluorescein instantly.
2. Maintain Patent Intravenous Access: DO NOT REMOVE THE IV CATHETER OR BUTTERFLY NEEDLE. Tape it securely and immediately flush with 0.9% normal saline. Maintaining established venous access is life-critical; peripheral veins collapse rapidly during anaphylactic shock, making emergent recannulation nearly impossible.
3. Call for Immediate Resuscitative Assistance: Activate the internal cardiac arrest team (Code Blue) or dial emergency medical services (911).
4. Patient Positioning:
   • For Hypotension / Anaphylactic Shock / Syncope: Place the patient in the Trendelenburg position (supine with lower extremities elevated 30° to 45°) to augment venous return to the heart and preserve cerebral perfusion.
   • For Laryngeal Stridor / Respiratory Distress: Maintain the patient in an upright or semi-Fowler's position if conscious to optimize diaphragmatic excursion, provided blood pressure is stable.
5. Airway, Breathing, Circulation (ABCs): Maintain an open airway; initiate bag-valve-mask ventilation if respiratory effort is compromised. Administer high-flow supplemental oxygen via a non-rebreather reservoir mask at 10 to 15 L/min.

First-Line Pharmacotherapy: Intramuscular Epinephrine

Epinephrine (Adrenaline) is the definitive, mandatory first-line medication for severe anaphylaxis, laryngeal edema, and acute bronchospasm. Antihistamines and corticosteroids are secondary adjuncts and must never delay epinephrine administration.

• Formulation: 1:1,000 dilution (1 mg/mL aqueous solution).
• Adult Dosage: 0.3 mg to 0.5 mg (0.3 to 0.5 mL).
• Route and Site: Administered Intramuscularly (IM) into the anterolateral aspect of the middle third of the thigh (vastus lateralis). The vastus lateralis provides vastly superior vascular absorption and achieves therapeutic plasma concentrations significantly faster than subcutaneous injection or deltoid intramuscular administration.
• Repeat Dosing: May be repeated every 5 to 15 minutes depending on clinical response, blood pressure, and airway patency.
• Pediatric Dosage: 0.01 mg/kg body weight of 1:1,000 IM (maximum single dose 0.3 mg).
• Dangers of Intravenous Epinephrine: Intravenous bolus injection of 1:1,000 epinephrine is strictly contraindicated due to the extreme risk of lethal ventricular tachyarrhythmias, malignant hypertension, and myocardial infarction. (IV epinephrine is reserved exclusively for cardiac arrest or profound shock managed by critical care physicians using a 1:10,000 dilution titrated under continuous cardiac monitoring).

Secondary Emergency Pharmacotherapy Protocols

---

Special Clinical Populations, Risk Factors, and Premedication

Patients Receiving Systemic Beta-Adrenergic Antagonists (Beta-Blockers)

Patients taking systemic beta-adrenergic antagonists (e.g., propranolol, metoprolol, atenolol, carvedilol) or topical ophthalmic beta-blockers (e.g., timolol) who experience severe anaphylaxis present a grave clinical scenario:

• Pathophysiological Dilemma: Beta-blockade renders the patient resistant to the therapeutic effects of epinephrine. The beta-2 bronchodilating and beta-1 inotropic actions of epinephrine are blunted, while unopposed alpha-adrenergic stimulation can induce severe peripheral vasoconstriction, worsening coronary ischemia and bronchoconstriction.
• The Antidote: Intravenous Glucagon: Glucagon exerts positive inotropic, chronotropic, and bronchodilating effects that are completely independent of beta-adrenergic receptors. Glucagon binds to specific glucagon receptors that directly activate intracellular adenylate cyclase via Gs proteins, generating cyclic AMP (cAMP) and reversing refractory shock and bronchospasm.
• Dose: 1 to 5 mg IV administered over 5 minutes, followed by a continuous infusion of 1 to 5 mg/hour titrated to hemodynamic recovery.

Renal Impairment, End-Stage Renal Disease, and Hemodialysis Protocols

• Renal Excretion: Because sodium fluorescein is cleared primarily via glomerular filtration, patients with chronic kidney disease (CKD) experience prolonged clearance, with chromaturia and yellow skin discoloration persisting for several days.
• Nephrotoxicity Assessment: Unlike radiopaque iodinated contrast media, sodium fluorescein is not inherently nephrotoxic at standard diagnostic doses (500 mg). It does not induce acute tubular necrosis or contrast-induced nephropathy.
• Hemodialysis Patients: Sodium fluorescein is water-soluble, has low molecular weight (376 Da), and is efficiently cleared by hemodialysis. Angiography can be performed safely; scheduling the procedure on the day of or the morning immediately preceding regularly scheduled hemodialysis facilitates rapid systemic clearance.

Pregnancy and Lactation Safety Guidelines

1. Pregnancy (FDA Category C):
   • Sodium fluorescein rapidly traverses the placental barrier and enters fetal circulation, appearing in amniotic fluid.
   • Although animal studies have not demonstrated teratogenicity, adequate well-controlled studies in pregnant women do not exist.
   • Clinical Standard: Fluorescein angiography should be avoided during pregnancy, particularly during the first trimester of organogenesis, unless an acute, sight-threatening condition (e.g., suspected choroidal neovascularization, occlusive vasculitis, or ocular tumor) leaves no diagnostic alternative.
2. Lactation / Breastfeeding Protocol:
   • Sodium fluorescein is actively excreted into human breast milk for up to 48 hours post-injection.
   • Ingested fluorescein enters infant circulation. Because infant skin and immature retinas are thin and highly vulnerable to light-induced damage, exposure to blue daylight can trigger phototoxic reactions in infants with circulating fluorescein.
   • Mandatory Clinical Instruction: Nursing mothers must be instructed to express and discard (pump and dump) breast milk for 24 to 48 hours following sodium fluorescein administration before resuming direct breastfeeding.

Prophylactic Premedication Regimen for Documented Prior Reactors

If fluorescein angiography is medically essential in a patient with a documented history of a prior mild-to-moderate allergic reaction, a formal oral corticosteroid and antihistamine premedication protocol must be executed:

Standard 13-Hour Prophylactic Premedication Protocol:
1. Prednisone 50 mg orally ──► 13 hours prior to angiography
2. Prednisone 50 mg orally ──► 7 hours prior to angiography
3. Prednisone 50 mg orally ──► 1 hour prior to angiography
4. Diphenhydramine 50 mg PO ──► 1 hour prior to angiography
(Optional: Add Famotidine 20 mg orally 1 hour prior to angiography)

Clinical Caution: Premedication significantly reduces the incidence of mild and moderate cutaneous reactions (urticaria, rash), but it does not guarantee absolute protection against severe anaphylactic shock. Full emergency resuscitative readiness is mandatory for all procedures.